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Abstract
Background: Surgery remains the only curative option for patients with colorectal cancer liver
metastases (CRLM). Perioperative chemotherapeutic strategies have become increasingly popular in the
treatment of CRLM. Although the role of bevacizumab (Bev) in this setting remains unclear, its widespread
use has raised concerns about the use of Bev as part of perioperative chemotherapy.
Methods: We retrospectively reviewed all patients who received Bev and underwent liver resection
between July 2004 and July 2008 at the McGill University Health Center. Chemotherapy-related toxicity,
response to chemotherapy, surgical morbidity and mortality, liver function and survival data were
assessed.
Results: A total of 35 patients were identified. Of these, 26 (74.3%) patients received oxaliplatin-based
cytotoxic chemotherapy, six (17.1%) received irinotecan-based therapy and the remainder received both
agents. A total of 17 patients (48.6%) underwent portal vein embolization prior to resection and 12
(34.3%) underwent staged resection for extensive bilobar disease. A median of six cycles of preoperative
Bev were administered. Nine patients (25.7%) experienced grade 3 or higher chemotherapy-related
toxicities. Four events were deemed to be related to Bev. The overall response rate was 65.7% (complete
and partial response). One patient progressed on therapy, but this did not prevent R0 resection. The
incidence of postoperative morbidity was 42.3%. A total of 21.7% of complications were Clavien grade
3 or higher. There were no perioperative mortalities. There were no cases of severe sinusoidal injury or
steatohepatitis. The Kaplan–Meier estimate of 4-year survival was 52.5%.
Conclusions: These data confirm the safety of chemotherapy regimens which include Bev in the
perioperative setting and demonstrate that such perioperative chemotherapy in patients with CRLM does
not adversely affect patient outcome. There was no increase in perioperative morbidity compared with
published rates. The addition of Bev to standard chemotherapy may improve response rates, which may,
in turn, impact favourably on patient survival.
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Introduction
Colorectal cancer is the third most common cancer in North
America, and is the third leading cause of cancer-related death.
The American Cancer Society estimates that about 108 070 new
cases of colon cancer and 40 740 new cases of rectal cancer will
have emerged in 2008 in the USA. Combined, these will cause
about 49 960 deaths.1 Approximately 50% of patients will be diag-
nosed with colorectal cancer liver metastasis (CRLM) during the
course of their disease.2 Around 20–25% of patients will have
synchronous liver metastases (LM) at presentation3 and a further
20–25% will develop metachronous LMs at a later date.
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Surgical resection remains the only curative therapy for patients
with CRLM. The most recently published series have seen the
5-year survival rate rise beyond 60%4–7 The progress can be attri-
buted to improvements in surgical techniques, perioperative care
and the emergence of more effective chemotherapy regimens.
However, only 20% of patients presenting with liver metastases
are amenable to surgical resection.8
There is a growing body of evidence supporting the use of
preoperative chemotherapy to downsize tumours and enable
surgery for patients with initially unresectable disease. In a ret-
rospective review, systemic chemotherapy demonstrated the
ability to convert 13% of patients with initially unresectable
CRLM to resectable status with a postoperative 5-year survival
rate of 33%.9Other reports have also demonstrated the use of
chemotherapy regimens to downstage the size of tumours in
order to convert unresectable tumours to resectable status. The
recently published Eloxatin® for peri-operative use (EPOC)
trial (European Organization for Research and Treatment of
Cancer [EORTC] 40893), conducted by Nordlinger’s group, is
the first randomized trial of perioperative chemotherapy to
demonstrate a progression-free survival advantage for patients
using this strategy.10 However, other publications highlight the
liver toxicities and potential perioperative morbidity and mor-
tality associated with preoperative chemotherapy.11,12 Another
potential advantage of perioperative chemotherapy was recently
proposed by Blazer et al. from MD Anderson Cancer Center.13
In their paper, the authors highlight the importance of response
to preoperative chemotherapy as a predictor of postoperative
outcome. It would therefore seem logical to choose the chemo-
therapy with the highest response rate in the preoperative
setting.
The perioperative use of bevacizumab ([Bev] Avastin™;
Hoffmann-Laroche, Basel, Switzerland), a humanized monoclonal
antibody that targets vascular endothelial growth factor (VEGF),
remains controversial. Although the survival benefit of Bev used in
the palliative setting has been established,14 its impact on response
rate is not as clear as recent data from the NO16966 trial failed to
show an increased response rate when Bev was combined with
FOLFOX-4.15 Despite this, Bev is commonly used in combination
with cytotoxic chemotherapy before surgical resection in patients
with CRLM. Because of reports of haematologic toxicity, intestinal
perforation and an increased risk of postoperative bleeding, sur-
geons and oncologists have been reluctant to use Bev in the perio-
perative setting. However, a retrospective study from the MD
Anderson showed no significant increase in hepatobiliary or
wound complications, and no postoperative deaths in patients who
received preoperative Bev.16 In the same series, only 12% of patients
experienced preoperative adverse events related to Bev therapy.
Other series have also confirmed that the neoadjuvant use of Bev in
combination with cytotoxic agents did not significantly increase
postoperative complications.17–19 In the current study, we review
our experience with a Bev and oxaliplatin-based chemotherapy
regimen administered to patients with CRLM perioperatively in
order to determine the safety and efficacy of this regimen and its
impact on survival.
Materials and methods
This retrospective review was authorized according to institutional
protocol by the Director of Professional Services at McGill Univer-
sity Health Centre. Patients who had undergone liver resection
between July 2004 and July 2008 at the McGill University Health
Centre and who had received Bev in the perioperative period were
identified through the hepatopancreatobiliary (HPB) database. All
patients who received Bev and underwent liver resection for CRLM
were included.
A total of 45 patients who had received Bev combined with
cytotoxic chemotherapy were identified. Of these, 10 had received
Bev only in the adjuvant setting for recurrent disease. The remain-
ing 35 are the focus of this analysis. Basic demographic data,
disease-specific data, information on the chemotherapy regimens
administered, chemotherapy-related toxicities, perioperative data,
imaging data, pathology reports and survival data were collected
and reviewed. Postoperative complications were reviewed and
graded according to the Clavien classification system20 The
primary objective of the study was to examine the effect of the
addition of Bev on treatment-related toxicity and perioperative
morbidity. Secondary outcomes included response to therapy as
determined by Response Evaluation Criteria in Solid Tumours
(RECIST) criteria21 and the effect of this therapy on overall patient
survival.
Although the actual chemotherapy regime to be used on a
patient was decided at the discretion of the treating oncologist, the
decision was guided by HBP Tumor Board recommendations.
The strategy generally employed comprised 12 cycles of chemo-
therapy, of which six were administered preoperatively and six
postoperatively. A break of 6–8 weeks between the last dose of Bev
and surgery was targeted. Staged resections and portal vein embo-
lization (PVE) were used liberally in this patient group. Response
to treatment and resectability were assessed at a weekly multidis-
ciplinary HPB Tumor Board meeting.
All patients underwent full preoperative assessment including
liver function tests and cross-sectional imaging with computed
tomography (CT), magnetic resonance imaging (MRI) and
CT-positron emission tomography (PET) as indicated. All CTs
and CT-PETs were reviewed by a radiologist. A RECIST classifi-
cation was used to assess treatment response. In addition, degree
of liver steatohepatitis and fibrosis staging scores were reviewed
on pathology specimens as per Kleiner et al.22 Finally, liver dys-
function was defined for every patient post-surgery intervention
using the scoring system established by Schindl et al.23 This
scoring system is based on the peak bilirubin, international
normalized ratio (INR), lactic acid and presence of encephalopa-
thy, and has been correlated with clinical outcomes23 and
measures of hepatic synthetic function (indocyanine green
clearance).24
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Data were analysed using spss 17.0 (SPSS, Inc., Chicago, IL,
USA). stata 9.2 (StataCorp LP, College Station, TX, USA) was
used for Kaplan–Meier estimation of survival.
Results
Overview
A total of 35 patients who received perioperative Bev with cyto-
toxic chemotherapy and underwent liver resection for CRLM were
identified. Their median age was 57 years (range 41–78 years); 24
(68.6%) patients were male (Table 1). The colon was the primary
site in 31 patients (88.6%). All patients were Eastern Cooperative
Oncology Group (ECOG) status 2 or lower. The median number
of lesions per patient was three (range 1–13). Twelve patients
(34.3%) underwent staged resections for major bilobar disease
involvement. Seventeen patients (48.6%) underwent PVE prior to
resection.
In all, 26 (74.3%) patients received oxaliplatin-based cytotoxic
chemotherapy. Six (17.1%) patients received irinotecan-based
therapy and the remainder received both perioperatively. A
median of six (range 4–16) cycles of Bev were administered pre-
operatively and a median of six (range 0–12) cycles were given
postoperatively. The median delay between the last dose of Bev
and surgery was 8 weeks (range 6–14 weeks).
Chemotherapy-related toxicity
Chemotherapy-related toxicities occurred in approximately two-
thirds of patients (Table 2). Thirteen (37.1%) patients had no
significant toxicity related to chemotherapy. Nine patients
(25.7%) had toxicities of grade 3 or higher. Three (8.6%) patients
experienced grade 4 toxicities, all of which were gastrointestinal in
origin. Only four toxicity events were deemed to be directly
related to Bev; these concerned one patient who developed an
anaphylactic reaction, two patients with hypertension, and one
patient with a significant episode of epistaxis. There were no arte-
rial thromboembolic events or gastrointestinal perforations.
Response to chemotherapy
Response rate was assessed according to RECIST criteria (Table 3).
The overall response rate was 65.7% (complete response and
partial response). A total of 21 patients (31.4%) achieved stable
disease. Only one patient progressed while on preoperative che-
motherapy, but this did not prevent an R0 resection.
Perioperative data
A total of 35 patients underwent 41 hepatectomies. Overall, 22
right hepatectomies, seven left hepatectomies, seven left lateral
sectionectomies, two extended right hepatectomies and three
segmental resections were performed. The median blood loss was
1100 ml (range 200–4000 ml). Mean duration of surgery was
185 min (range 95–350 min). The majority of patients (70.7%)
did not require intraoperative transfusion.
Postoperative complications
There were no perioperative mortalities in this series. The overall
incidence of morbidity was 42.3% (Table 4). A total of 23 compli-
cations occurred in 15 patients. Of these, only five (21.7%) were
grade 3 or higher according to the Clavien system.20 Ten patients
experienced 13 infectious complications (five urinary tract infec-
tions, four wound infections, one episode of Clostridium difficile
diarrhoea, one central line infection, one pneumonia and one
intra-abdominal abscess). Two patients had bile leaks, and one
Table 1 Baseline characteristics
Age, years (range) 57 (41–78)
Gender, M/F, n 24/11
Primary site
Colon, n (%) 31 (88.6%)
Rectum, n (%) 4 (11.4%)




Portal vein embolization, n (%) 17 (48.6%)
CTX regimen
CPT-11, n (%) 6 (19.4%)
Oxaliplatin, n (%) 26 (72.2%)
Both, n (%) 3 (8.3%)
Median cycles BV
Preoperative, n (range) 6 (4–16)
Postoperative, n (range) 6 (0–12)
Time from last Bev to surgery, weeks (range) 8 (6–14)
Median follow-up, years (range) 2.9 (1–6)
M, male; F, female; CTX, chemotherapy; CPT-11, irinotecan; Bev,
bevacizumab







Table 3 Response to chemotherapy
Response by RECIST n (%)
Progressive disease 1 (2.9%)
Stable disease 11 (31.4%)
Partial response 21 (60.0%)
Complete response 2 (5.7%)
RECIST, Response Evaluation Criteria in Solid Tumours
HPB 39
HPB 2010, 12, 37–42 © 2009 International Hepato-Pancreato-Biliary Association
required intervention by endoscopic retrograde cholangiopancre-
atography (ERCP). The second patient required revision of hepati-
cojejunostomy 3 months after the initial surgery. One patient had a
perioperative myocardial infarction requiring angioplasty and
stenting during the same admission. There was one anastomotic
dehiscence in the only patient who underwent a closure of ileo-
stomy at the same time as his liver resection; this required a second
surgical intervention. One patient had a small bowel obstruction
which resolved with conservative management. The average liver
function score as per Schindl et al.23 was 3 (moderate dysfunction).
Only two patients developed severe liver dysfunction. In one case,
the patient developed grade 3 hepatic encephalopathy after the
second resection of a staged procedure. In addition, he developed
jaundice (peak bilirubin 80 mmol/l), elevation of INR (peak 1.7)
and elevation of lactic acid (peak 4.2). These returned to normal by
postoperative day 7. In the second case, after an extended left
hepatectomy, the patient developed jaundice (peak bilirubin
83.5 mmol/l), elevation of INR (peak 1.8), and elevated lactic acid
(peak 3.6).She developed a late leak from her hepaticojejunostomy,
which was revised 3 months after the original surgery.
Chemotherapy-associated toxicity
Twenty-four patients (68%) demonstrated some degree of steato-
sis in the resection specimens, of which six cases (17.1%) were
moderate. Only four patients (11.4%) had steatohepatitis in the
resected liver (three mild, one moderate) and there were no cases
of severe steatohepatitis. No specimen demonstrated significant
sinusoidal injury.
Survival
The median follow-up for this group of patients is 2.9 years. The
Kaplan–Meier calculated 4-year survival is 52.5%. Median sur-
vival has not yet been reached (Fig. 1).
Discussion
The frequency of perioperative treatment strategies in the treat-
ment of CRLM continues to increase despite a relative lack of
prospective data to support their use. Proponents of these strate-
gies cite the opportunity to downsize tumours and in some cases
render unresectable tumours resectable, as well as the opportunity
to identify non-responders to chemotherapy who are unlikely to
benefit from surgical resection. Even among those who espouse
the use of perioperative chemotherapy, there has been reluctance
to add antiangiogenic agents for fear of increasing perioperative
morbidity and mortality, especially when the primary tumour has
not yet been resected. Certainly, there are reports of increased
bleeding, delayed wound healing and even intestinal perforation
associated with the use of Bev.25
The concerns about increased perioperative complications are
not limited to the antiangiogenic agents alone, as the occurrence
of steatosis and steatohepatitis, and sinusoidal injury related to
irinotecan and oxaliplatin, respectively, is now well character-
ized.11,26 Initial data also pointed to increased mortality associated
with steatohepatitis,27 although this has not been reported in all
series.28 Clearly even proponents of perioperative chemotherapy
agree that it is vital to limit preoperative exposure to chemo-
therapy. The EPOC trial was designed with this in mind, limiting
preoperative chemotherapy to only six cycles. At this exposure, the
occurrence of sinusoidal injury has been shown to be low.29
Although the trial was negative for its primary endpoint,
progression-free survival was increased in the patients who under-
went perioperative chemotherapy and liver resection. This trial
has provided the strongest evidence to date of the benefits of
perioperative chemotherapy.
Several studies have examined the pathologic response of
CRLM to preoperative chemotherapy. Znajda et al. evaluated a
series of resection specimens, and developed a classification for
these designated ‘remnants of uncertain malignant potential’.30
More recently, the MD Anderson group has proposed response to
chemotherapy as a significant prognostic indicator in patients
undergoing liver resection for CRLM.13 If response to preoperative
chemotherapy is indeed a prognostic factor, then it follows that
improving response to preoperative therapy should also improve
patient prognoses. It is clear that there is an increase in response
rate when Bev is added to cytotoxic therapy.14
The present series reports on a cohort of 35 patients with
CRLM who underwent liver resection and received perioperative
Bev and cytotoxic chemotherapy. The incidence and severity of
toxicity caused by the chemotherapy were low in this series (only
three patients with grade 4 events), in keeping with previous
reports.31 Only four toxicity events were attributable to Bev.
Table 4 Postoperative complications

















Figure 1 Survival after perioperative bevacizumab
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Perioperative morbidity occurred in 42.3% of patients, in
keeping with recent reports from MD Anderson and Memorial
Sloan Kettering Cancer Center (MSKCC).13,17 There were no mor-
talities. Because of concerns about wound healing after exposure
to Bev, it is our strict policy to wait at least 6 weeks from the last
dose of Bev to perform surgery. On a cautionary note, when bowel
anastomosis and liver resection were combined, the patient suf-
fered an anastomotic dehiscence.
This is the first series to report on the use of perioperative Bev
in patients undergoing staged resection. In the 12 patients who
underwent staged resections, there was no increase in periopera-
tive morbidity, length of stay or severity of liver dysfunction after
the second resection. Bev was avoided between the staged proce-
dures. In addition, 18 patients in this series underwent PVE. There
were no complications as a result of the procedure and adequate
hypertrophy of the future liver remnant occurred in all cases.
The overall response rate to preoperative chemotherapy includ-
ing Bev was 65.7%. This is among the highest response rates
reported in the surgical literature. Only one patient had progressive
disease and this did not prevent R0 resection. In addition, this is one
of the first surgical series to report survival rates of patients with
advanced CRLM undergoing perioperative chemotherapy includ-
ing Bev.With a median follow-up of 2.9 years, the 4-year survival is
52.5%. Both the survival and response rates are particularly prom-
ising given that the patients included in this analysis received Bev
before it became widely available at our institution. These patients
therefore represent a subgroup of patients who were considered to
have worse prognoses and were thus prescribed Bev.
Conclusions
In summary, these data demonstrate that the use of perioperative
chemotherapy containing Bev in patients with CRLM does not
adversely affect patient outcomes. There was no increase in perio-
perative morbidity and zero mortality. This compares favourably
with published rates. These data confirm the safety of chemo-
therapy regimens including Bev used in the perioperative setting.
The addition of Bev to standard chemotherapy may improve
response rates and, in the light of recently published data, this
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